SOURCE: Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc.

November 02, 2011 10:51 ET

Stellar Biotechnologies to Submit Documents for Registration of Shares in the U.S.

PORT HUENEME, CA--(Marketwire - Nov 2, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce they have retained A.B. Korelin & Associates Inc. of Blaine, WA to assist the Company in its preparation and submission of the Company's Form 20-F Registration Statement with the Securities & Exchange Commission ("SEC").

Filing of the Form 20-F is a necessary first step in Stellar's strategy to expose U.S. stockbrokers to the Company. Stellar plans to accomplish this through a wide-ranging series of ongoing investor forums in the United States at which time the features of the Company will be outlined.

Once the Form 20-F becomes effective with SEC, Stellar becomes a fully reporting issuer in the United States. It will also allow the Company to consider the advantages of listing on one of the U.S. exchanges.

Stellar CEO Frank Oakes said, "Filing of the Form 20-F will require the Company to file registration statements, periodic reports, and other forms through EDGAR. When registered, Stellar will provide analysts, brokers and institutions in the U.S. the confidence that the Company is registered with the SEC, and will assist them in discussing the Company with American residents. Registration will also allow anyone access to SEC registered information on the Company by way of the Internet."

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Contact Information

  • Contact:
    Darrell Brookstein
    Exec VP, Corporate Development & Finance
    322 Scott Street, Port Hueneme, CA 93041
    (805) 488-2147 ext. 103
    dbrookstein@stellarbiotech.com